kuljit singh - Infectious Diseases

Author Information

Kuljit Singh is affiliated with the Infectious Diseases Division at the CSIR-Indian Institute of Integrative Medicine in Jammu, India. Additionally, he is connected with the Academy of Scientific and Innovative Research (AcSIR) in Ghaziabad, India. His research largely focuses on infectious diseases, as evident from his institutional affiliations and body of work.

Research Contributions

Kuljit Singh has contributed significantly to the field of medical research, with a diverse range of publications spanning various topics. In 2022, he published work on the therapeutic applications of probiotics and their regulatory framework. In 2021, his research explored a variety of subjects including pharmacotherapy for MINOCA, the efficacy of smoking cessation treatments, advancements in leishmaniasis diagnostics and therapeutics, and the role of drug therapy in managing pregnancy-induced hypertension. Singh has also conducted systematic reviews and meta-analyses on mortality in spontaneous coronary artery dissection and cardiac complications following mRNA COVID-19 vaccinations. His work reflects a broad interest in both infectious and non-infectious disease domains.

Aliases

There are no aliases mentioned for Kuljit Singh in the provided data.

Publication and Citation Metrics

Metric	Value
Total Citation Count	1851
H-index	23
Paper Count	145

Publications:

Therapeutic applications of probiotics and its regulatory framework

DOI: 10.1016/b978-0-12-823966-7.00027-x

Year: 2022

Comparing pharmacotherapy in MINOCA versus medically managed obstructive acute coronary syndrome

DOI: 10.1007/s00380-021-01956-2

Year: 2021

Correction: Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): A randomized controlled clinical trial

DOI: 10.1371/journal.pone.0262188

Year: 2021

Advancement in leishmaniasis diagnosis and therapeutics: An update.

DOI: 10.1016/j.ejphar.2021.174436

Year: 2021

Pregnancy-induced hypertension: Role of drug therapy and nutrition in the management of hypertension

DOI: 10.1016/J.PHANU.2021.100251

Year: 2021

Mortality in spontaneous coronary artery dissection: A systematic review and meta-analysis.

DOI: 10.1002/ccd.29488

Year: 2021

Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019.

DOI: 10.1093/eurjpc/zwab213

Year: 2021

Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment for Post Infarct Angina in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries: A MINOCA-BAT Sub Study Rationale and Design

DOI: 10.3389/fcvm.2021.717526

Year: 2021

Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study

DOI: 10.1007/s10557-021-07240-9

Year: 2021

Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series.

DOI: 10.1002/rmv.2318

Year: 2021

What are the Challenges in Infectious Disease Education?

How Do We Address the Challenge of Antimicrobial Resistance?

Why is Drug Resistance a Concern?

What Role Does Genomic Structure Play in Antimicrobial Resistance?

How Long Does It Take to Get Results?

What are the limitations of RT-PCR?

Are There Any Concerns About Drug Resistance?

What is the Role of the Zika Virus in Microcephaly?

What Technologies are Used in Genomic and Proteomic Studies?

Why is Quarantine Necessary?

Partnered Content Networks

Relevant Topics